← Eichor
Condition: B Cell Leukemia Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: B Cell Leukemia

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Blinatumomab for Relapsed Acute B Lymphoblastic Leukemia After Transplantation
Phase 4 · 1 location(s) · Suping ZHANG · NCT06339775Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL
Phase 2 · 3 location(s) · Massachusetts General Hospital · NCT04560322Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Smal
Phase 2 · 7 location(s) · City of Hope Medical Center · NCT07218510Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma
Phase N/A · 2 location(s) · Emory University · NCT03501576Developing a Patient-Reported Outcome (PRO) Screening Measure for Infections and Measuring Quality of Life in Hematologi
Phase N/A · 5 location(s) · Medical University Innsbruck · NCT06821880In VIVO CAR-T Therapy for Relapsed/Refractory Hematological Malignancies
Phase 1 · 1 location(s) · Chongqing Precision Biotech Co., Ltd · NCT07239323Effectiveness and Safety of Tisagenlecleucel Therapy in Brazilian Patients With B-lymphocyte Malignancies
Phase N/A · 7 location(s) · Novartis Pharmaceuticals · NCT05541341Allogeneic CARCIK-CD19 in Adults/Pediatric B-cell NHL or Chronic Lymphocytic Leukemia
Phase 1/Phase 2 · 1 location(s) · Fondazione Matilde Tettamanti Menotti De Marchi Onlus · NCT05869279A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in
Phase 1 · 2 location(s) · Mayo Clinic · NCT03017820Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-cell Malignancies U
Phase N/A · 1 location(s) · Mayo Clinic · NCT06151730Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and
Phase 1/Phase 2 · 26 location(s) · Sellas Life Sciences Group · NCT04588922Donor Derived CD19 CAR-T Cells in the Treatment of R/R B-cell Acute Lymphoblastic Leukemia
EARLY_Phase 1 · 1 location(s) · Zhejiang University · NCT06793241AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
Phase 1/Phase 2 · 80 location(s) · AstraZeneca · NCT06137118A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
Phase 4 · 38 location(s) · Eli Lilly and Company · NCT06876649Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy)
Phase 1/Phase 2 · 1 location(s) · Stephan Grupp MD PhD · NCT05480449Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological M
Phase 2 · 1 location(s) · Fred Hutchinson Cancer Center · NCT04195633A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Pa
Phase 1 · 3 location(s) · City of Hope Medical Center · NCT07020533Impact of Targeted Therapy on Cancer-Related Cognitive Impairment
Phase N/A · 1 location(s) · University of Rochester NCORP Research Base · NCT07638007The Effects of Exercise on Immune Phenotype of Indolent Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia Patients
NA · 2 location(s) · Mayo Clinic · NCT05876923Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms
Phase N/A · 1 location(s) · iOMEDICO AG · NCT06043011Combination of an Anti-PD1 Antibody With Tisagenlecleucel Reinfusion in Children, Adolescents and Young Adults With Acut
Phase 1/Phase 2 · 13 location(s) · Assistance Publique - Hôpitaux de Paris · NCT05310591CAR-T Cell Therapy for ALL
EARLY_Phase 1 · 1 location(s) · Dr. Zaineb Akram · NCT07695012Treatment of CD19 Chimeric Antigen Receptor T Cells for Pediatric Patients With CD19-positive B-cell Acute Lymphoblastic
Phase 2 · 1 location(s) · Seoul National University Hospital · NCT06247501Exploratory Study of CD22/CD19 Dual-Target CAR-T Cell Therapy as Consolidation Treatment After First Remission in High-R
Phase 1/Phase 2 · 1 location(s) · Liping Dou · NCT07575971HPC Offered for PRESERVE Expansion
Phase N/A · 4 location(s) · Ossium Health, Inc. · NCT07145411Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies
Phase 1 · 9 location(s) · Exscientia AI Ltd., a wholly owned subsidiary of Recursion P · NCT06980116Safety, Tolerability, and Pharmacokinetics of Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-deri
Phase 1 · 1 location(s) · Beijing GoBroad Hospital · NCT06326008Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias
Phase 1/Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT06364423B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide
Phase 1 · 1 location(s) · Mayo Clinic · NCT06191887Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, o
Phase 2 · 278 location(s) · National Cancer Institute (NCI) · NCT03739814
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.